We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Comparison of long-term effects of lymphoblastoid interferon alpha and recombinant interferon alpha-2a therapy in patients with chronic hepatitis B.
- Authors
Lin, S.-M.; Tai, D.-I.; Chien, R.-N.; Sheen, I.-S.; Chu, C.-M.; Liaw, Y.-F.
- Abstract
To compare the long-term effect of natural lymphoblastoid interferon-alpha (IFN- αnl) and recombinant IFN- α2a therapy in patients with chronic hepatitis B, 210 patients in two trials were followed-up for 1.1–15.5 years following the end of therapy. They included 34 patients who received placebo (control), 67 treated with IFN- αnl (36 after prednisolone priming) and 109 treated with IFN- α2a (56 after prednisolone priming). The cumulative sustained response was higher in patients who had been treated with IFN- αnl after prednisolone priming than was exhibited using IFN- αnl alone, IFN- α2a alone or the placebo ( P < 0.05), or IFN- α2a following prednisolone priming ( P = 0.052) at the end of 11 years. Hepatocellular carcinoma (HCC) was detected in 1.5% of the IFN- αnl group, 3.7% of the IFN- α2a group and 14.7% of the control group (control vs IFN- αnl or IFN- α2a, P < 0.05). The cumulative HCC development was higher in the control group than in the IFN- αnl group ( P < 0.002) and the IFN- α2a group ( P = 0.06). The cumulative survival rate was lower in the control group than in the IFN- αnl group ( P < 0.01) and the IFN- α2a group ( P = 0.02). Multivariate analysis revealed that IFN- αnl therapy and female gender are significant predictors of sustained response; preexisting cirrhosis, age at entry and IFN therapy are significant factors in both HCC development and survival. In conclusion, IFN- αnl treatment may have a better long-term effect on hepatitis B virus (HBV) clearance than IFN- α2a and placebo, and IFN therapy may provide better long-term beneficial effects than placebo in terms of HBV clearance, reduction of HCC and prolonged survival.
- Subjects
INTERFERONS; HEPATITIS B treatment; CHRONIC disease treatment; LIVER cancer; THERAPEUTICS
- Publication
Journal of Viral Hepatitis, 2004, Vol 11, Issue 4, p349
- ISSN
1352-0504
- Publication type
Article
- DOI
10.1111/j.1365-2893.2004.00512.x